Travere Therapeutics price target raised to $20 from $18 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on Travere Therapeutics to $20 from $18 and keeps a Buy rating on the shares after having hosted an attending nephrologist to discuss the committee’s resolution at the conclusion of the PARASOL Scientific Workshop. The expert reported enthusiasm for using proteinuria as a primary endpoint in clinical studies and if this is adopted by regulators, the decision has “clear positive implications” for Filspari, the analyst tells investors. The firm is adding focal segmental glomerulosclerosis, or FSGS, back into its model, “conservatively” assuming a 2025 launch and odds of success of 45%, the analyst noted.